Hims & Hers Faces a Critical Year as Growth Trajectory Shifts

Hims & Hers projects sharp 2026 growth slowdown to 15% amid FDA, DOJ, and Novo Nordisk legal pressure on its weight-loss segment, triggering major analyst downgrades.

The telehealth company Hims & Hers is navigating a complex set of challenges that threaten to reshape its business model. Investors are confronting a starkly different outlook for 2026, marked by a significant growth deceleration and mounting legal pressures, particularly in its lucrative weight management segment.

Regulatory and Legal Headwinds Intensify

A primary concern is escalating scrutiny from U.S. regulators. Reports indicate that in February, the Food and Drug Administration (FDA) referred the company to the Department of Justice concerning a compounded version of a popular weight-loss drug. Furthermore, the FDA is considering adding the active ingredient semaglutid to a list of substances that can no longer be compounded by pharmacies—a move that would fundamentally disrupt the company's diet sector operations.

The legal challenges extend beyond regulators. Pharmaceutical giant Novo Nordisk has filed a lawsuit against the telehealth platform, alleging improper marketing of compounded versions of its blockbuster drugs Wegovy and Ozempic. This is compounded by a separate investigation by the Securities and Exchange Commission (SEC), which became public last month.

Financial Forecasts Signal a Sharp Slowdown

The company's financial guidance for 2026 reveals a dramatic shift. Management now projects revenue growth of just over 15%, a steep decline from the 59% growth anticipated for 2025. The weight-loss segment, once a major growth driver, is now expected to create a headwind of approximately $65 million in the first quarter of 2026.

Profit margins are also under pressure from costly international expansion efforts. Recent acquisitions, including the entry into the UK market via Zava and a deal worth up to $1.15 billion with Australia's Eucalyptus, are weighing on finances. While leadership emphasizes the long-term sustainability of these moves, current figures tell a more cautious story.

Analysts Slash Targets as Share Price Plummets

The confluence of slowing growth and existential legal risks has prompted a severe reaction from Wall Street. Analysts have drastically reduced their price targets:
- Barclays cut its target from $48 to $25.
- Morgan Stanley nearly halved its expectations, lowering its target from $40 to $21.
- Citigroup and BTIG also downgraded the stock.

The market has already priced in these concerns. The shares are currently trading at €14.06, having lost more than 50% of their value since the start of the year.

For Hims & Hers, 2026 shapes up as a decisive test. The critical question is whether its aggressive international push can offset the declining momentum in its core U.S. business and the potential regulatory bans on its profitable weight-management offerings. Given the scale of the regulatory challenges, the answer remains highly uncertain.